Nordicus Partners Corp

Nordicus Partners Corporation has entered into a material definitive agreement by issuing a $147,000 Promissory Note to ABCHill Holding ApS. The note is payable on demand and accrues interest at a rate of 6.0% per annum or the maximum rate permitted by law. The lender is controlled by Christian Hill-Madsen, a director of several of the Company's subsidiaries. The issuance was made in reliance on the exemption from registration under Section 4(a)(2) of the Securities Act.

Nordicus Partners Corporation filed its 10-Q for the period ending June 30, 2026. The company reported a net loss of $2.31 million for the second quarter of 2026, an increase from the $1.21 million net loss in the same period of 2025. Revenue remained flat at $0 for both periods. Total assets decreased to $73.1 million, while total liabilities slightly increased to $11.6 million, resulting in a decrease in total stockholders' equity to $61.5 million. The company also noted a significant increase in net loss per share to ($0.13) from ($0.07) year-over-year.

Nordicus Partners Corp, a U.S. publicly listed biotech company, announced significant progress in its drug development pipeline, with Orocidin A/S and Bio-Convert A/S both anticipating Phase IIa clinical trials in the first half of 2027 for periodontitis and oral leukoplakia, respectively. The company also formed a new subsidiary, NoviThera ApS, in October 2025 to develop a psoriasis treatment, which has completed biological proof of concept. Additionally, Nordicus applied to uplist its common stock to the Nasdaq Capital Market in September 2025. Financially, the company saw increased cash usage in operating activities and higher R&D and professional fees for the fiscal year ended March 31, 2026.

Nordicus Partners Corporation announced that Andrew J. Ritter resigned from its Board of Directors, effective July 7, 2026. Mr. Ritter also stepped down from the Audit, Compensation, and Nominating and Corporate Governance Committees. The company stated that his resignation was to pursue other time-consuming business opportunities and was not due to any disagreement with the company's operations, policies, or practices.

Nordicus Partners Corp completed a private offering, issuing a total of 201,500 restricted shares of its common stock to five private investors at a price of $2.75 per share, raising $554,125. The shares were issued in March and April 2026, with the offering officially closing on June 23, 2026. The company claimed exemptions from registration for these unregistered sales of equity securities under Section 4(a)(2) and/or Rule 506(b) and (c) of Regulation D and Regulation S.